AR025324A1 - Composiciones farmaceuticas para la administracion oral y topica - Google Patents

Composiciones farmaceuticas para la administracion oral y topica

Info

Publication number
AR025324A1
AR025324A1 ARP000104281A ARP000104281A AR025324A1 AR 025324 A1 AR025324 A1 AR 025324A1 AR P000104281 A ARP000104281 A AR P000104281A AR P000104281 A ARP000104281 A AR P000104281A AR 025324 A1 AR025324 A1 AR 025324A1
Authority
AR
Argentina
Prior art keywords
ch2or
chor
ch2o
unsaturated
fatty acids
Prior art date
Application number
ARP000104281A
Other languages
English (en)
Original Assignee
Ivax Pharmaceuticals Sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10859192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR025324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Pharmaceuticals Sro filed Critical Ivax Pharmaceuticals Sro
Publication of AR025324A1 publication Critical patent/AR025324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)

Abstract

Un método para aumentar la viscosidad de una formulacion farmacéutica para la administracion oral o topica que comprende los pasos de combinar: a) unacantidad efectiva de uno o más ingredientes hidrofobicos activos; b) entre el 5 y el 50% de uno omá s compuestos seleccionados de poliglicerol ésteres deácidos grasos de la formula: CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]nCH2-CHOR-CH2OR, donde n es un entero entre 4 y 10 y R es H o CO.R donde R es un alquilo saturado, no saturado o hidroxilado C8-22, ydon de al menos un grupo R no es hidrogeno, c) entre el 5 y el 50% de uno o más compuestos seleccionados de poliglicerolésteres de ácidos grasos y/o ácidos grasos no saturados de la siguiente formula: CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]nCH2-CHOR-CH2ORdonde n es un entero entre 0-1y R = H o CO.R, donde R es un alquilo saturado, no saturado o hidrixalado de C8-22, y donde al menos un grupo R no es hidrogeno; d) entre el 5 y el 50% deuno o más compuestos seleccionados de macrogol glicerolésteres detrigli cérido, glicéridos parciales o ácidos grasos o macrogol ésteres de ácidos grasos dondela cantidad promedio del oxido etileno reaccionado en la síntesis de estas sustancias está dentro de un rango entre 50 y 150 moles y concurrentemente,larelacion en tre los componentes b) y d) es entre 0,1 : 1 a 10 : 1; donde los porcentajes anteriores se seleccionan hasta un total del 100%; y donde después dela dilucion con agua 1 : 1 en volumen, la viscosidad de la formulacion aumenta en almenos 5 veces compa rada con la composicion no diluida.
ARP000104281A 1999-08-17 2000-08-18 Composiciones farmaceuticas para la administracion oral y topica AR025324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9919288A GB2355656B (en) 1999-08-17 1999-08-17 Pharmaceutical compositions for oral and topical administration

Publications (1)

Publication Number Publication Date
AR025324A1 true AR025324A1 (es) 2002-11-20

Family

ID=10859192

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000104281A AR025324A1 (es) 1999-08-17 2000-08-18 Composiciones farmaceuticas para la administracion oral y topica
ARP030103268A AR043106A2 (es) 1999-08-17 2003-09-10 Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030103268A AR043106A2 (es) 1999-08-17 2003-09-10 Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica

Country Status (40)

Country Link
US (1) US20070190132A1 (es)
EP (2) EP1210119B1 (es)
JP (2) JP2003507343A (es)
KR (2) KR100828748B1 (es)
CN (2) CN1382061A (es)
AR (2) AR025324A1 (es)
AT (2) ATE288766T1 (es)
AU (1) AU777740B2 (es)
BR (1) BR0013385A (es)
CA (2) CA2380951C (es)
CO (1) CO5380014A1 (es)
CY (1) CY1105318T1 (es)
CZ (2) CZ296170B6 (es)
DE (2) DE60018081T2 (es)
DK (2) DK1210119T3 (es)
EE (2) EE04955B1 (es)
EG (1) EG23994A (es)
ES (2) ES2311077T3 (es)
GB (1) GB2355656B (es)
HK (1) HK1049629A1 (es)
HR (1) HRP20020154B1 (es)
HU (1) HUP0203236A3 (es)
IL (4) IL148200A0 (es)
JO (1) JO2324B1 (es)
MX (1) MXPA02001631A (es)
NO (2) NO20020760L (es)
NZ (1) NZ517271A (es)
PE (1) PE20010636A1 (es)
PL (1) PL192769B1 (es)
PT (2) PT1210119E (es)
RU (2) RU2279894C2 (es)
SA (1) SA00210487B1 (es)
SG (1) SG143019A1 (es)
SI (1) SI1210119T1 (es)
SK (2) SK286083B6 (es)
TN (1) TNSN00173A1 (es)
UA (2) UA72539C2 (es)
UY (1) UY26303A1 (es)
WO (1) WO2001012229A1 (es)
ZA (2) ZA200308221B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
FR2826261B1 (fr) * 2001-06-26 2005-03-25 Lmd Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
EP1935407A1 (en) * 2002-12-03 2008-06-25 Elan Pharma International Limited Low viscosity liquid dosage forms
EP1582206A4 (en) * 2002-12-04 2010-09-22 Nisshin Pharma Inc WATER-SOLUBLE COMPOSITION WITH COENZYM Q10
JP4518042B2 (ja) * 2002-12-04 2010-08-04 日油株式会社 コエンザイムｑ１０を含有する水溶性組成物の製造方法
CN104587479A (zh) 2002-12-09 2015-05-06 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
US8236286B2 (en) * 2004-10-20 2012-08-07 Kao Corporation Liquid compositions for the oral cavity
KR20080003322A (ko) * 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 도세탁셀 및 이의 유사체의 나노입자 배합물
NZ592647A (en) * 2008-11-28 2013-05-31 Lectio Pharmaentwicklungs Und Verwertungs Gmbh Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
PL2405892T3 (pl) * 2009-03-12 2013-10-31 Lectio Pharmaentwicklungs Und Verwertungs Gmbh Preparat farmaceutyczny zawierający ketoprofen i ester polioksyalkilenowy kwasu hydroksytłuszczowego
KR101100933B1 (ko) * 2009-04-23 2012-01-02 한국기술교육대학교 산학협력단 솔더 볼 제거 장치
KR20170131641A (ko) * 2015-03-27 2017-11-29 아치 퍼스널 케어 프로덕츠, 엘.피. 퍼스널 케어 제품용 점도 증강 조성물
CN112426403B (zh) * 2020-12-09 2021-09-17 南京天纵易康生物科技股份有限公司 一种口腔溃疡凝胶及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
CA2283780A1 (en) * 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
IL131609A0 (en) * 1997-03-12 2001-01-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
DE69823663T2 (de) * 1997-07-29 2005-05-19 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration

Also Published As

Publication number Publication date
ZA200201315B (en) 2004-06-30
BR0013385A (pt) 2002-05-07
CA2380951A1 (en) 2001-02-22
MXPA02001631A (es) 2003-07-14
HK1049629A1 (zh) 2003-05-23
UY26303A1 (es) 2001-03-16
DK1210119T3 (da) 2005-06-20
HUP0203236A2 (hu) 2003-01-28
PT1210119E (pt) 2005-05-31
ES2237443T3 (es) 2005-08-01
ES2311077T3 (es) 2009-02-01
CA2380951C (en) 2010-03-23
EP1334717B1 (en) 2008-07-30
JP2003507343A (ja) 2003-02-25
AR043106A2 (es) 2005-07-20
SG143019A1 (en) 2008-06-27
DE60018081T2 (de) 2006-01-05
EE200200075A (et) 2003-04-15
EE04954B1 (et) 2008-02-15
CZ296170B6 (cs) 2006-01-11
CO5380014A1 (es) 2004-03-31
AU6461300A (en) 2001-03-13
DE60322454D1 (de) 2008-09-11
DK1334717T3 (da) 2008-11-24
GB9919288D0 (en) 1999-10-20
PL353445A1 (en) 2003-11-17
CY1105318T1 (el) 2010-03-03
ATE402691T1 (de) 2008-08-15
ATE288766T1 (de) 2005-02-15
CN101406453A (zh) 2009-04-15
EE04955B1 (et) 2008-02-15
EP1210119A1 (en) 2002-06-05
SI1210119T1 (en) 2005-06-30
DE60018081D1 (de) 2005-03-17
JO2324B1 (en) 2005-09-12
KR20050095651A (ko) 2005-09-29
EP1210119B1 (en) 2005-02-09
HRP20020154B1 (en) 2006-07-31
JP2004238399A (ja) 2004-08-26
SA00210487B1 (ar) 2006-09-10
RU2003133451A (ru) 2005-04-20
GB2355656B (en) 2004-04-07
IL148200A (en) 2007-12-03
CZ2002575A3 (cs) 2003-05-14
PT1334717E (pt) 2008-10-09
UA75926C2 (en) 2006-06-15
SK286083B6 (sk) 2008-03-05
SK2482002A3 (en) 2002-12-03
EE200300371A (et) 2003-10-15
EP1334717A3 (en) 2004-01-02
PE20010636A1 (es) 2001-06-02
KR100828748B1 (ko) 2008-05-09
RU2279895C2 (ru) 2006-07-20
WO2001012229A1 (en) 2001-02-22
IL158108A0 (en) 2004-03-28
IL148200A0 (en) 2002-09-12
US20070190132A1 (en) 2007-08-16
AU777740B2 (en) 2004-10-28
GB2355656A (en) 2001-05-02
EG23994A (en) 2008-03-10
RU2279894C2 (ru) 2006-07-20
KR100828747B1 (ko) 2008-05-09
NO20034778L (no) 2002-04-16
NZ517271A (en) 2004-02-27
CA2452118A1 (en) 2001-02-22
HRP20020154A2 (en) 2003-12-31
HUP0203236A3 (en) 2004-06-28
UA72539C2 (en) 2005-03-15
NO20020760D0 (no) 2002-02-15
TNSN00173A1 (en) 2005-11-10
ZA200308221B (en) 2004-09-29
CZ296591B6 (cs) 2006-04-12
CN1382061A (zh) 2002-11-27
NO20020760L (no) 2002-04-16
IL158108A (en) 2010-04-15
PL192769B1 (pl) 2006-12-29
KR20020059367A (ko) 2002-07-12
NO20034778D0 (no) 2003-10-24
EP1334717A2 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
AR025324A1 (es) Composiciones farmaceuticas para la administracion oral y topica
ES2088254T5 (es) Compuesto detergente y metodo para su fabricacion.
PE20030742A1 (es) Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
KR890001521A (ko) 서방형 신규 제약 제제물
US4745103A (en) Hair cosmetic composition
PT999838E (pt) Formulacao auto-emulsionante para compostos lipofilicos
RU2496467C2 (ru) Композиции, пригодные для отбеливания зубов
EA018545B1 (ru) Терапевтические композиции
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
UA39896C2 (uk) Фармацевтична або ветеринарна композиція мупіроцину та спосіб її приготування
CO5080786A1 (es) Metodo para mejorar la penetracion de agentes beneficiosos usando determinadas formulaciones que contiene agentes tensoactivos/lipidos no ionicos como agente mejorado y las composiciones alli usadas
AR017801A1 (es) Una composicion de preconcentrado en microemulsion que contiene ciclosporina, y una formulacion farmaceutica que la comprende
RU2012130421A (ru) Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
RU2002106825A (ru) Фармацевтические композиции для перорального и местного применения
CZ215593A3 (en) Stable multiple emulsions, and process for preparing thereof
BR112021000482A2 (pt) Composições de esterquat
WO2016104698A1 (ja) アシル塩基性アミノ酸誘導体を含有するクリーム状洗浄剤組成物
US6548557B1 (en) Neutralization of phosphate esters, compositions based upon and methods using same
JP2010001218A (ja) 皮膚外用組成物および皮膚再生促進剤
JP2594553B2 (ja) 毛髪化粧料
RU2018129304A (ru) Новая улучшенная композиция, содержащая по меньшей мере один кадотрил
JP6968463B1 (ja) 外用組成物
JPH06256142A (ja) 養育毛剤
KR100656071B1 (ko) 구형의 라멜라 구조를 형성하는 피부 세정제 조성물
KR101461640B1 (ko) 산화성 액상 염모제 조성물

Legal Events

Date Code Title Description
FB Suspension of granting procedure